Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy CompanyNewsfile Corp • 06/01/23
TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/11/23
TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRRBusiness Wire • 04/26/23
Adaptimmune Shareholders Can Lock In A Big Merger Spread By Swapping To TCR2 TherapeuticsSeeking Alpha • 04/21/23
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 04/03/23
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/23/23
SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of TCR² Therapeutics Inc. - TCRRPRNewsWire • 03/06/23
Shareholder Alert: Ademi LLP investigates whether TCR² Therapeutics Inc. has obtained a Fair Price in its transaction with AdaptimmunePRNewsWire • 03/06/23
TCRR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of TCR² Therapeutics Inc. Is Fair to ShareholdersBusiness Wire • 03/06/23
Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid TumorsGlobeNewsWire • 03/06/23
Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid TumorsNewsfile Corp • 03/06/23
TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023GlobeNewsWire • 02/08/23
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 01/05/23
Down 16.6% in 4 Weeks, Here's Why You Should You Buy the Dip in TCR2 Therapeutics Inc. (TCRR)Zacks Investment Research • 11/11/22
TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/08/22
TCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of CancerGlobeNewsWire • 11/07/22
gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and MesotheliomaGlobeNewsWire • 09/28/22
TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid TumorsGlobeNewsWire • 09/27/22